Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹2,392 Cr
verified against source
Revenue YoY
6.5%
reported change
EBITDA
Pending
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
IPCA Laboratories delivered a solid Q3 FY26 with consolidated revenue of ₹2,245 crore (+6.5% YoY) and consolidated EBITDA margin expanding 228 bps YoY to 22.15%. Standalone EBITDA margin improved to 26.09% (+184 bps YoY). Growth was driven by strong domestic formulation performance (+12% YoY, outpacing IPM), robust export branded formulations (+17% YoY, led by West Africa +69%), and US business growth (+17% YoY). API business remained flat. Management guided for 10-12% revenue growth across segments and 150 bps annual EBITDA margin expansion, supported by product mix improvement and operating leverage. Key risks include continued market share loss at Unichem (US business) for 1-2 more quarters and pricing pressure in the UK generic market, though recent recovery is noted.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects 10-12% growth in domestic, branded exports, and generic businesses; API slightly lower.
- At 10-11% topline growth, EBITDA margin should improve by ~1.5% per year.
- Unichem aims for 15% EBITDA margin in 2-3 years, then gradually to 20% as European filings commercialize.
- IPA will commercialize 5-7 additional molecules in the US over next 12-15 months, adding to existing 5.
Risks flagged
- Unichem lost market share in key US products; decline may continue for 1-2 more quarters, pressuring margins.
- UK generic market experienced severe price erosion; though recent recovery of 30-40% seen, sustainability uncertain.
- US growth largely driven by IKA portfolio; organic IPA US business still small (~₹10-11M in 9 months).
- Promotional branded business is stable but can be impacted by currency fluctuations in emerging markets.
Key quotes
- Our domestic business for Q3 FY26 has delivered a growth of around 12% for the quarter.
- Our aim is to reach EBITDA margin to begin with around 15% maybe in 2-3 years time and gradually improve it to about 20%.
- We have about 35 registrations out of which five we have commercialized. Another five to seven molecule will get commercialized over next 12 to 15 months.
Research modules